$3.2 million per dose Elevidys fails to meet primary endpoint in phase 3 trial
submited by
Style Pass
2024-10-23 12:00:34
October 21, 2024 report
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: